Functional and hyperfunctional siRNA directed against Bcl-2
US7511132B2 · kind B2 · utility
72Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 16, 2007 |
| Grant date | Mar 31, 2009 |
| Priority date | — |
| Expiry date | Oct 16, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.